

U.S. Food and Drug Administration

Center for Drug Evaluation and Research

Errata to FDA Briefing Document

Antimicrobial Drugs Advisory Committee Meeting

November 30, 2021

On page 13 of the original FDA briefing document the relative risk reduction of MOV compared to placebo was reported as 52% (95% CI: 33%, 80%); however, the statement should read, “Relative risk reduction of MOV compared to placebo was 48% (95% CI: 20%, 67%) based on the Cochran-Mantel-Haenszel method stratified by time of COVID-19 symptom onset (≤ 3 days versus >3 [4 to 5] days).”